Current Illinois CancerCare Clinical Trials

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute
Lymphoblastic Leukemia (T-ALL)

Study Number: EA9213 (JIT)

Study Summary:
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Status: Open

Study Coordinator(s)
  • Navigator Heather, 309-243-3661
  • Hannah, 309-243-3628

Study Link

« Search Again